Breaking News Instant updates and real-time market news.

2020-04-22 09:13:37 KPTI Karyopharm $23.58 / -1.46 (-5.83%) 09:13 04/22/20 04/22 09:13 04/22/20 09:13	Karyopharm partners with Precision for Medicine for COVID-19 global trial Karyopharm is collaborating with Precision for Medicine, a designer and developer of biomarker-informed clinical studies and complex data management, to help conduct the first global randomized clinical trial for low dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. Precision for Medicine will oversee implementation of the clinical trial in Europe. Precision will be responsible for ensuring site engagement, obtaining regulatory and clinical governing authority approvals, collecting and monitoring data. "This latest alliance with Precision for Medicine builds on the successful submission and FDA approval for XPOVIO - selinexor -," said Karyopharm Chief Development Officer Ran Frenkel. "We have also collaborated on successful phase II and phase III clinical trials in haemato-oncological malignancies, as well as trials in therapeutic areas such as multiple myeloma, diffuse large B-cell lymphoma and acute myeloid leukemia."	21 May 23 Jun
KPTI Karyopharm $23.58 / -1.46 (-5.83%) 04/07/20 Wedbush Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID 04/07/20 H.C. Wainwright XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright 03/04/20 Barclays Karyopharm initiated with an Overweight at Barclays 03/03/20 Canaccord Karyopharm price target raised to $35 from $22 at Canaccord

2020-04-22 09:13:37

KPTI

Karyopharm

$23.58 / -1.46 (-5.83%)

09:13

04/22/20

04/22

09:13

04/22/20

09:13

Karyopharm partners with Precision for Medicine for COVID-19 global trial

Karyopharm is collaborating with Precision for Medicine, a designer and developer of biomarker-informed clinical studies and complex data management, to help conduct the first global randomized clinical trial for low dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. Precision for Medicine will oversee implementation of the clinical trial in Europe. Precision will be responsible for ensuring site engagement, obtaining regulatory and clinical governing authority approvals, collecting and monitoring data. "This latest alliance with Precision for Medicine builds on the successful submission and FDA approval for XPOVIO - selinexor -," said Karyopharm Chief Development Officer Ran Frenkel. "We have also collaborated on successful phase II and phase III clinical trials in haemato-oncological malignancies, as well as trials in therapeutic areas such as multiple myeloma, diffuse large B-cell lymphoma and acute myeloid leukemia."

21
May
23
Jun

KPTI Karyopharm

$23.58 / -1.46 (-5.83%)

04/07/20 Wedbush: Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID

04/07/20 H.C. Wainwright: XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright

03/04/20 Barclays: Karyopharm initiated with an Overweight at Barclays

03/03/20 Canaccord: Karyopharm price target raised to $35 from $22 at Canaccord

TODAY'S FREE FLY STORIES

Downgrade	BankUnited downgraded to Neutral from Buy at Janney Montgomery Scott » 07:31 03/03/21 03/03 07:31 03/03/21 07:31 BKU BankUnited $42.03 / -0.025 (-0.06%) Janney Montgomery Scott… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings BKU BankUnited $42.03 / -0.025 (-0.06%) 02/19/21 DA Davidson BankUnited downgraded to Neutral from Buy at DA Davidson 02/19/21 DA Davidson BankUnited downgraded to Neutral from Buy at DA Davidson 01/25/21 RBC Capital BankUnited price target raised to $42 from $39 at RBC Capital 01/08/21 UBS BankUnited downgraded to Neutral from Buy at UBS BKU BankUnited $42.03 / -0.025 (-0.06%) 01/21/21 BankUnited reports Q4 EPS 89c, consensus 70c 10/28/20 BankUnited reports Q3 EPS 70c, consensus 63c
Upgrade	Itron upgraded to Buy from Hold at Argus » 07:29 03/03/21 03/03 07:29 03/03/21 07:29 ITRI Itron $117.75 / -0.06 (-0.05%) Argus analyst John Eade… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ITRI Itron $117.75 / -0.06 (-0.05%) 02/17/21 Bsquare, Itron extend pact over industrial IoT innovation 01/19/21 Itron and Versant Power collaborate to modernize electricity grid in Maine 10/05/20 ON Semiconductor appoints Itron CEO Thomas Deitrich to board 10/05/20 Itron, Con Ed confirm, NYS affirmed its consent approval for Itron ERT module ITRI Itron $117.75 / -0.06 (-0.05%) 07:19 Today Argus Itron upgraded to Buy from Hold at Argus 02/25/21 Oppenheimer Itron price target raised to $127 from $75 at Oppenheimer 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James ITRI Itron $117.75 / -0.06 (-0.05%) 02/24/21 Itron sees FY21 EPS $2.15-$2.55, consensus $2.26 02/24/21 Itron reports Q4 EPS 65c, consensus 30c 11/02/20 Itron reports Q3 EPS 61c, consensus 25c 03/08/21 Itron
Recommendations	Otis Worldwide price target raised to $77 from $75 at Cowen » 07:29 03/03/21 03/03 07:29 03/03/21 07:29 OTIS Otis Worldwide $65.46 / +0.55 (+0.85%) Cowen analyst Cai Von… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events OTIS Otis Worldwide $65.46 / +0.55 (+0.85%) 02/10/21 Otis Worldwide selected to supply elevators, escalators in three Canadian cities 01/11/21 Otis Worldwide recommends shareholders reject TRC Capital 'mini-tender' offer 01/11/21 CVS Health names Laurie Havanec as Chief People Officer OTIS Otis Worldwide $65.46 / +0.55 (+0.85%) 10/07/20 JPMorgan Otis Worldwide price target raised to $79 from $75 at JPMorgan 09/24/20 Wolfe Research Otis Worldwide upgraded to Outperform from Peer Perform at Wolfe Research 09/24/20 JPMorgan Otis Worldwide pullback due to 'unwarranted concerns,' says JPMorgan 07/29/20 Credit Suisse Otis Worldwide price target raised to $66 from $55 at Credit Suisse OTIS Otis Worldwide $65.46 / +0.55 (+0.85%) 02/01/21 Otis Worldwide sees FY21 adjusted EPS $2.67-$2.77, consensus $2.62 02/01/21 Otis Worldwide reports Q4 non-GAAP EPS 66c, consensus 59c 10/26/20 Otis Worldwide raises FY20 adj. EPS view to $2.42 from $2.20-$2.30 10/26/20 Otis Worldwide reports Q3 adj. EPS 69c, consensus 56c OTIS Otis Worldwide $65.46 / +0.55 (+0.85%) 02/01/21 Fly Intel: Pre-market Movers 10/26/20 Fly Intel: Pre-market Movers 03/04/21 Otis Worldwide - OTIS
Hot Stocks	Anghami to list on Nasdaq New York via Vistas Media Acquisition Company merger » 07:28 03/03/21 03/03 07:28 03/03/21 07:28 VMAC Vistas Media Acquisition Company $10.25 / +0.05 (+0.49%) Anghami, a music… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Upgrade	Iridium upgraded to Outperform from Market Perform at Raymond James » 07:28 03/03/21 03/03 07:28 03/03/21 07:28 IRDM Iridium $39.45 / -2.47 (-5.89%) Raymond James analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings IRDM Iridium $39.45 / -2.47 (-5.89%) 02/19/21 Iridium CEO sells 62.1K shares of common stock 02/12/21 Collegium Pharmaceutical to replace Iridium in S&P 600 at open on 2/12 02/12/21 Iridium to replace Monolithic Power in S&P 400 at open on 2/12 02/10/21 Iridium board approves $300M share repurchase program IRDM Iridium $39.45 / -2.47 (-5.89%) 04:40 Today Raymond James Iridium upgraded to Outperform from Market Perform at Raymond James 02/12/21 Fly Intel: Top five analyst downgrades 02/12/21 Barclays Barclays double downgrades Iridium with stock ahead of fundamentals 02/12/21 Barclays Iridium downgraded to Underweight from Overweight at Barclays IRDM Iridium $39.45 / -2.47 (-5.89%) 02/11/21 Iridium sees FY21 service revenue growth of 3% 02/11/21 Iridium reports Q4 EPS (6c), consensus (8c) 10/20/20 Iridium reports Q3 EPS (3c), consensus (11c)

Recommendations	Ambarella price target raised to $137 from $125 at Morgan Stanley » 07:27 03/03/21 03/03 07:27 03/03/21 07:27 AMBA Ambarella $113.78 / -4.91 (-4.14%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options AMBA Ambarella $113.78 / -4.91 (-4.14%) 03/02/21 Ambarella jumps 7% to $121.95 after Q4 results top estimates 03/02/21 Motional selects Ambarella CVflow AI processors for driverless vehicles 01/11/21 Ambarella unveils CV5 AI vision processor with 8K capabilities 12/28/20 FAA adopts final rules for drones 'advancing opportunities' for utilization AMBA Ambarella $113.78 / -4.91 (-4.14%) 07:12 Today Stifel Ambarella price target raised to $135 from $128 at Stifel 02/24/21 Deutsche Bank Ambarella price target raised to $100 from $75 at Deutsche Bank 01/21/21 Stifel Ambarella price target raised to $118 from $110 at Stifel 01/13/21 Roth Capital Ambarella upgraded to Buy with $130 price target at Roth Capital AMBA Ambarella $113.78 / -4.91 (-4.14%) 03/02/21 Ambarella reports Q4 EPS 14c, consensus 8c 11/24/20 Ambarella sees Q4 revenue $56M-$60M, consensus $52.31M 11/23/20 Ambarella reports Q3 EPS 9c, consensus 5c AMBA Ambarella $113.78 / -4.91 (-4.14%) 03/02/21 Fly Intel: After-Hours Movers 12/14/20 Fly Insider: Molecular Templates, AMD among notable insider trades 12/07/20 Fly Insider: Foot Locker, Alexion among weeks notable insider trades 11/23/20 Fly Intel: After-Hours Movers 03/15/21 33rd Annual Roth Virtual Conference AMBA Ambarella $113.78 / -4.91 (-4.14%) 02/01/21 Ambarella call volume above normal and directionally bullish 01/21/21 Ambarella call volume above normal and directionally bullish 12/10/20 Ambarella call volume above normal and directionally bullish 12/03/20 Ambarella call volume above normal and directionally bullish
Recommendations	Columbia Sportswear price target raised to $130 from $116 at Cowen » 07:27 03/03/21 03/03 07:27 03/03/21 07:27 COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) Cowen analyst John Kernan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) 02/04/21 Columbia Sportswear board approves $400M share buyback increase 02/04/21 Columbia Sportswear restores 26c per share quarterly dividend 01/27/21 Columbia Sportswear names Skip Potter as Chief Digital Information Officer 01/06/21 Columbia Sportswear names Starbucks' John Culver to board of directors COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) 02/05/21 Baird Columbia Sportswear price target raised to $120 from $98 at Baird 12/09/20 BofA Columbia Sportswear cut to Neutral at BofA on more challenging near-term view 12/09/20 BofA Columbia Sportswear downgraded to Neutral from Buy at BofA 10/30/20 Baird Columbia Sportswear weakness a buying opportunity, says Baird COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) 02/04/21 Columbia Sportswear sees FY21 $3.75-$4.05 EPS , consensus $3.65 02/04/21 Columbia Sportswear reports Q4 EPS $1.44, consensus $1.24 02/04/21 Notable companies reporting after market close 10/29/20 Columbia Sportswear sees Q4 EPS $1.07-$1.32, consensus $1.59 COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) 10/22/20 Short-seller GlassHouse Research sees 51% downside for Columbia Sportswear COLM Columbia Sportswear $102.64 / -2.6 (-2.47%) 02/04/21 Fly Intel: After-Hours Movers 12/28/20 Fly Insider:180 Degree Capital, AMC among week's notable insider trades 10/29/20 Fly Intel: After-Hours Movers
Recommendations	Domino's Pizza price target lowered to $400 from $455 at Argus » 07:26 03/03/21 03/03 07:26 03/03/21 07:26 DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) Argus analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) 02/25/21 Domino's Pizza drops 7% to $339.21 after Q4 results miss estimates 02/25/21 Domino's Pizza announces new $1B share repurchase program 02/25/21 Domino's Pizza announces two- to three-year outlook for certain metrics 02/25/21 Domino's Pizza raises quarterly dividend 20.5% to 94c per share DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) 02/26/21 Wedbush Domino's Pizza price target lowered to $475 from $500 at Wedbush 02/26/21 JPMorgan Domino's Pizza share 'dislocation' buying opportunity, says JPMorgan 02/26/21 Credit Suisse Domino's Pizza price target lowered to $425 from $445 at Credit Suisse 02/26/21 UBS Domino's Pizza price target lowered to $370 from $430 at UBS DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) 02/25/21 Domino's Pizza reports Q4 adjusted EPS $3.46, consensus $3.89 02/25/21 Domino's Pizza reports Q4 EPS $3.46, consensus $3.89 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) 02/25/21 Fly Intel: Wall Street's top stories for Thursday 02/25/21 Fly Intel: Wall Street's top stories at midday 02/25/21 Fly Intel: Pre-market Movers 10/08/20 Fly Intel: Wall Street's top stories for Thursday DPZ Domino's Pizza $342.92 / -2.15 (-0.62%) 10/08/20 Unusually active option classes on open October 8th
Recommendations	Stifel buyers on weakness in Target, sees pullback as attractive entry point » 07:25 03/03/21 03/03 07:25 03/03/21 07:25 TGT Target $173.40 / -12.72 (-6.83%) Stifel analyst Mark… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TGT Target $173.40 / -12.72 (-6.83%) 03/02/21 Target plans to open five more sortation centers in 2021 03/02/21 Target plans to open 30-40 new stores each year 03/02/21 Target to open approx. 100 Ulta Beauty at Target shop-in-shops in 2021 03/02/21 Target plans to invest $4B annually during next several years TGT Target $173.40 / -12.72 (-6.83%) 03/02/21 Baird Target price target lowered to $200 from $220 at Baird 02/09/21 Jefferies Dollar General well-positioned to mitigate minimum wage headwind, says Jefferies 02/08/21 Fly Intel: Top five analyst upgrades 02/08/21 Stifel Target upgraded to Buy from Hold at Stifel TGT Target $173.40 / -12.72 (-6.83%) 03/02/21 Target reports Q4 adjusted EPS $2.67, consensus $2.54 03/01/21 Notable companies reporting before tomorrow's open 03/01/21 Notable companies reporting before tomorrow's open 11/18/20 Target reports Q3 total revenue $22.63B, consensus $20.93B TGT Target $173.40 / -12.72 (-6.83%) 02/26/21 Costco to hike minimum hourly wage to $16 an hour, WSJ reports 12/06/20 Chick-fil-A sues Tyson, others for poultry price-fixing, Bloomberg says 11/14/20 Targe booming during pandemic, stock still undervalued, Barron's says 10/24/20 Sprouts Farmers ready for rebound, Barron's says TGT Target $173.40 / -12.72 (-6.83%) 03/02/21 Fly Intel: Wall Street's top stories for Tuesday 03/02/21 Fly Intel: Wall Street's top stories at midday 03/01/21 Fly Intel: What to watch in Target's earnings report 02/26/21 Fly Intel: Wall Street's top stories at midday TGT Target $173.40 / -12.72 (-6.83%) 03/02/21 Early notable gainers among liquid option names on March 2nd 03/02/21 Unusually active option classes on open March 2nd 11/19/20 Early notable gainers among liquid option names on November 19th 11/17/20 Unusually active option classes on open November 17th
General news	FX Update: The dollar has seen a down-and-up price action » 07:25 03/03/21 03/03 07:25 03/03/21 07:25 FX Update: The dollar has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Hot Stocks	Purple Biotech appoints Robert Gagnon to board of directors » 07:24 03/03/21 03/03 07:24 03/03/21 07:24 PPBT Purple Biotech $4.44 / -0.3 (-6.33%) , VSTM Verastem $2.38 / -0.06 (-2.46%) Purple Biotech (PPBT)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options PPBT VSTM PPBT Purple Biotech $4.44 / -0.3 (-6.33%) 12/10/20 Kitov Pharmaceuticals announces name change to Purple Biotech VSTM Verastem $2.38 / -0.06 (-2.46%) 02/24/21 Verastem posts abstract with data on VS-6766 01/19/21 Chiasma appoints John Doyle as CFO 12/15/20 Verastem begins Phase 2 registration, directed trial of VS-6766 and defactinib 11/30/20 Verastem initiates Phase 2 registration-directed clinical trial of VS-6766 PPBT VSTM PPBT Purple Biotech $4.44 / -0.3 (-6.33%) 12/31/20 H.C. Wainwright H.C. Wainwright reiterates Buy, $25 price target on Purple Biotech VSTM Verastem $2.38 / -0.06 (-2.46%) 04/27/20 JonesTrading Verastem downgraded to Hold from Buy at JonesTrading 04/23/20 Cantor Fitzgerald Verastem's market cap could double with positive data, says Cantor Fitzgerald 03/20/20 JonesTrading Verastem upgraded to Buy from Hold at JonesTrading VSTM VSTM Verastem $2.38 / -0.06 (-2.46%) 11/09/20 Verastem reports Q3 EPS 11c, consensus 4c PPBT VSTM PPBT Purple Biotech $4.44 / -0.3 (-6.33%) 12/22/20 Four new option listings and six option delistings on December 22nd VSTM Verastem $2.38 / -0.06 (-2.46%) 12/04/20 Largest borrow rate increases among liquid names 12/03/20 Largest borrow rate increases among liquid names
Recommendations	Deckers Brands price target raised to $435 from $365 at Cowen » 07:24 03/03/21 03/03 07:24 03/03/21 07:24 DECK Deckers Brands $325.50 / -5.53 (-1.67%) Cowen analyst John Kernan… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly DECK Deckers Brands $325.50 / -5.53 (-1.67%) 02/05/21 Baird Deckers Brands price target raised to $415 from $325 at Baird 02/05/21 Jefferies Deckers Brands price target raised to $400 from $346 at Jefferies 02/05/21 Cowen Deckers Brands price target raised to $365 from $330 at Cowen 02/05/21 Wells Fargo Deckers Brands price target raised to $360 from $284 at Wells Fargo DECK Deckers Brands $325.50 / -5.53 (-1.67%) 02/04/21 Deckers Brands reports Q3 EPS $8.99, consensus $7.07 10/29/20 Deckers Brands not providing full year guidance for fiscal year 2021 10/29/20 Deckers Brands reports Q2 EPS $3.58, consensus $2.63 DECK Deckers Brands $325.50 / -5.53 (-1.67%) 10/29/20 Fly Intel: After-Hours Movers
Hot Stocks	Lantronix announces Mobile HDK featuring Qualcomm Snapdragon 888 » 07:23 03/03/21 03/03 07:23 03/03/21 07:23 LTRX Lantronix $4.72 / -0.11 (-2.28%) , QCOM Qualcomm $136.37 / -2.48 (-1.79%) Lantronix (LTRX)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LTRX QCOM LTRX Lantronix $4.72 / -0.11 (-2.28%) 02/17/21 Lantronix launches EDS3000 serial-to-Ethernet servers 11/18/20 Lantronix provides IoT technologies to Youbiquo for AR smart glasses 11/11/20 Lantronix launches connectivity services to simplify connecting IoT fleets 10/20/20 Lantronix supports creation of Embodied's Moxie QCOM Qualcomm $136.37 / -2.48 (-1.79%) 02/16/21 Appaloosa buys Macy's and Kohl's, exits AT&T in Q4 02/09/21 Globalstar announces inclusion of Band n53 in Qualcomm's X65 modem 02/03/21 Qualcomm down 7% to $151.01 after Q1 earnings, Q2 outlook 01/26/21 Veoneer, Qualcomm to collaborate on scalable ADAS/AD solutions LTRX QCOM LTRX Lantronix $4.72 / -0.11 (-2.28%) 05/15/20 Lake Street Lantronix 'relatively upbeat tone' encouraging, says Lake Street 03/12/20 Lake Street Lantronix price target lowered to $5 from $6 at Lake Street QCOM Qualcomm $136.37 / -2.48 (-1.79%) 02/10/21 JPMorgan China mobile shipments data point to 'robust' Apple demand, says JPMorgan 02/08/21 JPMorgan JPMorgan prefers shares of Qualcomm over Apple 02/04/21 Fly Intel: Top five analyst downgrades 02/04/21 Qualcomm price target raised to $150 from $126 at RBC Capital LTRX QCOM LTRX Lantronix $4.72 / -0.11 (-2.28%) 02/11/21 Lantronix sees FY21 EPS up 75%-125%, consensus 6c 02/11/21 Lantronix reports Q2 EPS 3c, consensus 5c 11/12/20 Lantronix sees FY21 revenue growth of 20%-25% 11/12/20 Lantronix reports Q1 EPS 5c, consensus 5c QCOM Qualcomm $136.37 / -2.48 (-1.79%) 02/03/21 Qualcomm sees Q2 EPS $1.55-$1.75, consensus $1.57 02/03/21 Qualcomm reports Q1 EPS $2.17, consensus $2.10 02/03/21 Notable companies reporting after market close 11/04/20 Qualcomm sees Q1 adjusted EPS $1.95-$2.15, consensus $1.68 QCOM QCOM Qualcomm $136.37 / -2.48 (-1.79%) 02/24/21 Biden to address chip shortages with executive action, WSJ reports 02/12/21 Tech companies seek intervention in Nvidia acquisition of Arm, Bloomberg says 02/12/21 FTC opened in-depth investigation of Nvidia's ARM deal, Bloomberg reports 02/12/21 Qualcomm expresses concern over Nvidia's $40B Arm takeover, CNBC reports LTRX QCOM LTRX Lantronix $4.72 / -0.11 (-2.28%) 11/12/20 Fly Intel: After-Hours Movers QCOM Qualcomm $136.37 / -2.48 (-1.79%) 02/27/21 Charged: Tesla temporarily halts Model 3 line at CA plant 02/24/21 Fly Intel: What to watch in Nvidia earnings report 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/04/21 Fly Intel: Wall Street's top stories for Thursday 03/15/21 33rd Annual Roth Virtual Conference 04/28/21 Qualcomm - QCOM 03/04/21 Qualcomm 03/10/21 Qualcomm Inc. QCOM QCOM Qualcomm $136.37 / -2.48 (-1.79%) 12/07/20 Qualcomm call buyer realizes 32% same-day gains 12/04/20 Qualcomm call volume above normal and directionally bullish 11/11/20 Qualcomm call volume above normal and directionally bullish 11/11/20 Early notable gainers among liquid option names on November 11th
Hot Stocks	Rubicon Organics enters extraction services agreement with Valens Company » 07:22 03/03/21 03/03 07:22 03/03/21 07:22 ROMJF Rubicon Organics $0.00 / + (+0.00%) , VLNCF Valens Company $0.00 / + (+0.00%) Rubicon Organics Inc.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ROMJF ROMJF Rubicon Organics $0.00 / + (+0.00%) 12/29/20 Rubicon Organics receives first purchase order from Quebec 12/14/20 Rubicon Organics appoints Julie Lassonde to board of directors 11/25/20 Rubicon Organics expects to achieve monthly positive cash flow in 1H21 ROMJF VLNCF ROMJF Rubicon Organics $0.00 / + (+0.00%) 05/14/20 Canaccord Rubicon Organics initiated with a Speculative Buy at Canaccord VLNCF Valens Company $0.00 / + (+0.00%) 02/26/21 Stifel Valens Company price target raised to C$3.75 from C$3.35 at Stifel 02/26/21 Canaccord Valens Company price target lowered to C$3.50 from C$4.50 at Canaccord 02/01/21 Canaccord Valens Company price target lowered to C$4.50 from C$6 at Canaccord 02/01/21 Stifel Valens Company price target raised to C$3.35 from C$3.25 at Stifel ROMJF ROMJF Rubicon Organics $0.00 / + (+0.00%) 11/25/20 Rubicon Organics reports Q3 EPS (C$0.09) vs. (C$0.12) last year VLNCF VLNCF Valens Company $0.00 / + (+0.00%) 12/17/20 Rising High: 2021 predictions for the cannabis industry
Recommendations	Lemonade price target raised to $130 from $105 at JMP Securities » 07:21 03/03/21 03/03 07:21 03/03/21 07:21 LMND Lemonade $110.46 / -21.895 (-16.54%) JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options LMND Lemonade $110.46 / -21.895 (-16.54%) 03/02/21 Lemonade falls -10.5% 03/02/21 Lemonade falls -10.0% 01/21/21 Lemonade director sells 65.5K shares of common stock 01/14/21 Lemonade falls -4.9% LMND Lemonade $110.46 / -21.895 (-16.54%) 01/21/21 Piper Sandler Lemonade price target raised to $163 from $105 at Piper Sandler 11/23/20 Morgan Stanley Root initiated with an Equal Weight at Morgan Stanley 11/12/20 Piper Sandler Lemonade price target raised to $71 from $63 at Piper Sandler 11/02/20 Piper Sandler Lemonade initiated with an Overweight at Piper Sandler LMND Lemonade $110.46 / -21.895 (-16.54%) 03/01/21 Lemonade sees FY21 revenue $114M-$117M, consensus $111.33M 03/01/21 Lemonade sees Q1 revenue $21.5M-$22.5M, consensus $22.11M 03/01/21 Lemonade reports Q4 EPS (60c), consensus (64c) 03/01/21 Notable companies reporting after market close 14 Jan 02 Jul LMND Lemonade $110.46 / -21.895 (-16.54%) 01/14/21 Lemonade shares heading back to $100, Citron Research says 01/14/21 Citron cautious on Lemonade, says shares going back to $100 12/31/20 Short seller Friendly Bear sees Lemonade falling '90%+ in short order' LMND Lemonade $110.46 / -21.895 (-16.54%) 03/02/21 Fly Intel: Pre-market Movers 03/01/21 Fly Intel: After-Hours Movers 01/12/21 Fly Intel: Pre-market Movers 12/28/20 Before the Move: Watch Lemonade into stock lockup expiration LMND Lemonade $110.46 / -21.895 (-16.54%) 01/22/21 Largest borrow rate increases among liquid names 01/21/21 Largest borrow rate increases among liquid names 01/15/21 Largest borrow rate increases among liquid names 01/07/21 Largest borrow rate increases among liquid names

Hot Stocks	Profound Medical appoints Cynthia Lavoie to board of directors » 07:21 03/03/21 03/03 07:21 03/03/21 07:21 PROF Profound Medical $22.49 / -0.4 (-1.75%) Profound Medical… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Events PROF Profound Medical $22.49 / -0.4 (-1.75%) 12/21/20 Profound Medical, GE Healthcare partner to expand provider access to TULSA-PRO 11/30/20 Profound Medical receives FDA HDE approval for Sonalleve 11/30/20 Profound Medical appoints Murielle Lortie to board of directorsLiminal BioSciences PROF Profound Medical $22.49 / -0.4 (-1.75%) 01/25/21 Lake Street Profound Medical price target raised to $32 from $27 at Lake Street 01/07/21 Alliance Global Partners Profound Medical price target raised to $28.25 from $20.25 at Alliance Global 09/15/20 Jefferies Profound Medical initiated with a Buy at Jefferies 09/10/20 Lake Street Profound Medical initiated with a Buy at Lake Street 16 Jul 03/02/21 41st Annual Healthcare Virtual Conference
Initiation	Equillium initiated with a Buy at JonesTrading » 07:20 03/03/21 03/03 07:20 03/03/21 07:20 EQ Equillium $7.20 / -0.25 (-3.36%) JonesTrading analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly EQ Equillium $7.20 / -0.25 (-3.36%) 02/12/21 Equillium presents 'positive' interim clinical data on Itolizumab trial in aGVHD 02/09/21 Equillium appoints Katherine Xu to board of directors 12/21/20 Equillium appoints Dolca Thomas as CMO, EVP, R&D 12/07/20 Equillium presents translational data on itolizumab EQ Equillium $7.20 / -0.25 (-3.36%) 11/30/20 H.C. Wainwright Equillium price target lowered to $12 from $22 at H.C. Wainwright 07/14/20 H.C. Wainwright Equillium price target raised to $24 from $14 at H.C. Wainwright 07/10/20 Stifel Equillium transferred with Buy rating, $10 target at Stifel EQ Equillium $7.20 / -0.25 (-3.36%) 11/10/20 Equillium reports Q3 EPS (31c), consensus (40c) 14 Aug EQ Equillium $7.20 / -0.25 (-3.36%) 11/10/20 Fly Intel: After-Hours Movers 10/30/20 Fly Intel: Wall Street's top stories for Friday 10/30/20 Fly Intel: Wall Street's top stories at midday 10/30/20 Fly Intel: Pre-market Movers
Hot Stocks	Green Thumb Industries announces partnership with Cann » 07:20 03/03/21 03/03 07:20 03/03/21 07:20 GTBIF Green Thumb Industries $0.00 / + (+0.00%) Green Thumb Industries… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events GTBIF Green Thumb Industries $0.00 / + (+0.00%) 02/01/21 Green Thumb Industries to open Rise Erie Peach in Pennsylvania 12/31/20 Green Thumb announces resignation of board member Alex Yemenidjian 11/12/20 Green Thumb Industries CEO says cannabis market similar to online gaming 11/12/20 Green Thumb CEO sees cannabis growing 20% annually for next decade GTBIF Green Thumb Industries $0.00 / + (+0.00%) 02/25/21 Stifel Green Thumb Industries price target raised to C$71.50 from C$46 at Stifel 02/11/21 Cantor Fitzgerald Green Thumb Industries price target raised to $62 from $35 at Cantor Fitzgerald 02/02/21 Craig-Hallum Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum 01/20/21 Roth Capital Green Thumb Industries price target raised to $40 from $29 at Roth Capital GTBIF Green Thumb Industries $0.00 / + (+0.00%) 11/12/20 Rising High: Cannabis companies report earnings 09/03/20 Rising High: Cannabis firms report second quarter earnings 03/15/21 33rd Annual Roth Virtual Conference 03/17/21 Green Thumb Industries - GTBIF
Upgrade	Itron upgraded to Buy from Hold at Argus » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 ITRI Itron $117.75 / -0.06 (-0.05%) Argus analyst John Eade… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ITRI Itron $117.75 / -0.06 (-0.05%) 02/17/21 Bsquare, Itron extend pact over industrial IoT innovation 01/19/21 Itron and Versant Power collaborate to modernize electricity grid in Maine 10/05/20 ON Semiconductor appoints Itron CEO Thomas Deitrich to board 10/05/20 Itron, Con Ed confirm, NYS affirmed its consent approval for Itron ERT module ITRI Itron $117.75 / -0.06 (-0.05%) 02/25/21 Oppenheimer Itron price target raised to $127 from $75 at Oppenheimer 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James 01/08/21 Raymond James Itron downgraded to Outperform from Strong Buy at Raymond James 10/15/20 Stephens Itron resumed with an Overweight at Stephens ITRI Itron $117.75 / -0.06 (-0.05%) 02/24/21 Itron sees FY21 EPS $2.15-$2.55, consensus $2.26 02/24/21 Itron reports Q4 EPS 65c, consensus 30c 11/02/20 Itron reports Q3 EPS 61c, consensus 25c 03/08/21 Itron
Initiation	BlackRock TCP Capital resumed with an Outperform at JMP Securities » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 TCPC BlackRock TCP Capital / + JMP Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Earnings TCPC BlackRock TCP Capital / + 02/26/21 Raymond James BlackRock TCP Capital upgraded to Outperform from Market Perform at Raymond James 02/26/21 Raymond James BlackRock TCP upgraded to Outperform from Market Perform at Raymond James 06/24/20 Raymond James TCP Capital downgraded to Market Perform from Outperform at Raymond James 06/24/20 Raymond James TCP Capital downgraded to Market Perform from Outperform at Raymond James TCPC BlackRock TCP Capital / + 11/02/20 BlackRock TCP Capital reports Q3 NII 35c, consensus 32c

Hot Stocks	Kamada closes aquisition of FDA-licensed plasma collection center » 07:19 03/03/21 03/03 07:19 03/03/21 07:19 KMDA Kamada $6.10 / -0.1 (-1.61%) Kamada updated that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options KMDA Kamada $6.10 / -0.1 (-1.61%) 02/24/21 Kamada files 2020 annual report 02/10/21 Kamada to continue to focus on expanding existing growth drivers 02/01/21 Kamada acquires plasma collection center from Blood and Plasma Research 01/13/21 Kamada enters two agreements for distribution of three biosimilar products KMDA Kamada $6.10 / -0.1 (-1.61%) 08/14/20 Chardan Kamada price target raised to $11 from $7 at Chardan KMDA Kamada $6.10 / -0.1 (-1.61%) 02/10/21 Kamada reports Q4 EPS 4c, consensus 7c 11/11/20 Kamada reaffirms FY20 revenue view $132M-$137M, consensus $134.75M 11/11/20 Kamada reports Q3 EPS 15c, consensus 6c KMDA Kamada $6.10 / -0.1 (-1.61%) 09/16/20 Eight new option listings and one option delisting on September 16th
Upgrade	Roku upgraded to Overweight at KeyBanc on video monetization » 07:18 03/03/21 03/03 07:18 03/03/21 07:18 ROKU Roku $389.13 / -31.09 (-7.40%) , NLSN Nielsen $24.83 / +1.74 (+7.54%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 03/01/21 Roku to acquire Nielsen's video advertising business 02/18/21 Roku CEO says FY21 revenue growth to fall below levels of Q1 and Q2 02/18/21 Roku reports Q4 Active accounts 51.2M vs. 36.9M last year 01/21/21 Cinedigm launches All3Media's streaming channel SO... REAL App on Roku NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/01/21 Roku to acquire Nielsen's video advertising business 02/25/21 Twitter exploring 'super follows,' users able to subscribe for exclusive content 02/16/21 Elliott buys Evergy, exits eBay in Q4 01/12/21 Nielsen begins tracking premium theatrical films distributed via streaming ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 04:40 Today KeyBanc Roku upgraded to Overweight from Sector Weight at KeyBanc 02/22/21 Needham Roku price target raised to $550 from $400 at Needham 02/19/21 Truist Roku price target raised to $480 from $390 at Truist 02/19/21 JPMorgan Roku price target raised to $525 from $475 at JPMorgan NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/02/21 Truist Nielsen price target raised to $26 from $20 at Truist 03/01/21 Truist Nielsen price target raised to $26 from $20 at Truist 01/28/21 Citi Nielsen price target raised to $27 from $22 at Citi 11/03/20 Deutsche Bank Nielsen price target lowered to $18 from $22 at Deutsche Bank ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/18/21 Roku sees Q1 revenue $478M-$493M, consensus $462.97M 02/18/21 Roku reports Q4 EPS 49c, consensus (5c) 02/18/21 Notable companies reporting after market close 11/05/20 Roku reports Q3 EPS 9c, consensus (40c) NLSN Nielsen $24.83 / +1.74 (+7.54%) 02/25/21 Nielsen sees FY21 adjusted EPS $1.43-$1.54, consensus $1.66 02/25/21 Nielsen reports Q4 adjusted EPS 53c, consensus 46c 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 17 Mar ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/16/21 Streaming device maker Roku is hiring to make original content, Protocol says 02/11/21 ViacomCBS working on '60 Minutes' spinoff for Paramount+, Bloomberg says 01/04/21 Roku in advanced talks to buy Quibi's content catalog, WSJ reports 12/02/20 Roku hires Apple's chief Siri architect Brian Pinkerton, Bloomberg reports NLSN Nielsen $24.83 / +1.74 (+7.54%) 10/27/20 Nielsen in talks with PE group about $2.9B sale of consumer goods unit, FT says ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 03/01/21 Fly Intel: After-Hours Movers 02/19/21 Fly Intel: Wall Street's top stories for Friday 02/19/21 Fly Intel: Wall Street's top stories at midday 02/19/21 Fly Intel: Pre-market Movers NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/01/21 Fly Intel: After-Hours Movers 11/02/20 Fly Intel: Wall Street's top stories for Monday 11/02/20 Fly Intel: Wall Street's top stories at midday 11/02/20 Fly Intel: Pre-market Movers ROKU NLSN ROKU Roku $389.13 / -31.09 (-7.40%) 02/18/21 Roku options imply 13.2% move in share price post-earnings 01/07/21 Roku call volume above normal and directionally bullish 10/09/20 Unusual call flow in option market yesterday 10/08/20 Roku leads single-stock options after open as shares jump on upgrade NLSN Nielsen $24.83 / +1.74 (+7.54%) 03/02/21 Early notable gainers among liquid option names on March 2nd 12/04/20 Unusual call flow in option market yesterday 12/03/20 Bulls tune in to calls on Nielson Holdings 11/02/20 Early notable gainers among liquid option names on November 2nd
Recommendations	Stratasys price target raised to $34 from $14 at Loop Capital » 07:17 03/03/21 03/03 07:17 03/03/21 07:17 SSYS Stratasys $32.27 / -4.12 (-11.32%) Loop Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/01/21 Stratasys expects Q1 revenue to track similarly to 1Q20 02/18/21 Stratasys acquires U.K.-based RP Support Ltd., terms not stated 02/18/21 Stratasys acquires RPS, provider of best-in-class' stereolithography 3D printers 12/09/20 Stratasys to acquire Origin for total consideration of up to $100M SSYS Stratasys $32.27 / -4.12 (-11.32%) 01/19/21 Stifel Stratasys initiated with a Buy at Stifel 01/15/21 JPMorgan Stratasys downgraded to Underweight from Neutral at JPMorgan 10/09/20 Berenberg Stratasys initiated with a Buy at Berenberg 09/24/20 Fly Intel: Top five analyst downgrades SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/01/21 Stratasys reports Q4 EPS 13c, consensus 0c 11/12/20 Stratasys reports Q3 non-GAAP EPS (5c), consensus (7c) 03 Mar SSYS Stratasys $32.27 / -4.12 (-11.32%) 03/02/21 Fly Intel: After-Hours Movers 03/01/21 Fly Intel: Pre-market Movers SSYS Stratasys $32.27 / -4.12 (-11.32%) 02/25/21 Stratasys call volume above normal and directionally bullish 01/07/21 Stratasys call volume above normal and directionally bullish 12/17/20 Stratasys call volume above normal and directionally bullish
Hot Stocks	Qiwi CFO Pavel Korzh resigns » 07:17 03/03/21 03/03 07:17 03/03/21 07:17 QIWI Qiwi $11.11 / +0.12 (+1.09%) QIWI announced that Pavel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/10/20 Qiwi sinks after Central Bank of Russia puts restrictions on Qiwi Bank 11/19/20 Qiwi appoints Pavel Korzh as CFO QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/11/20 Goldman Sachs Qiwi downgraded to Neutral from Buy at Goldman Sachs 12/10/20 William Blair Qiwi government audit to bring business changes, says William Blair 12/09/20 JPMorgan Qiwi downgraded to Underweight from Neutral at JPMorgan 11/23/20 Qiwi downgraded to Sell from Buy at Sberbank CIB QIWI Qiwi $11.11 / +0.12 (+1.09%) 11/19/20 Qiwi reports Q3 EPS 61c, consensus 60c 22 Jul QIWI Qiwi $11.11 / +0.12 (+1.09%) 12/10/20 Fly Intel: Wall Street's top stories for Thursday 12/10/20 Fly Intel: Wall Street's top stories at midday QIWI Qiwi $11.11 / +0.12 (+1.09%) 03/01/21 Largest borrow rate increases among liquid names
Recommendations	TTEC Holdings price target raised to $110 from $90 at Canaccord » 07:16 03/03/21 03/03 07:16 03/03/21 07:16 TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) Canaccord analyst Joseph… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 TTEC Holdings raises semi-annual dividend by 7.5% to 43c per share 01/21/21 TTEC Holdings partners with Schwan's Home Delivery 12/03/20 TTEC Holdings declares special, one-time cash dividend of $2.14 per share 09/28/20 TTEC Holdings increases semi-annual cash dividend to 40c per share TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 12/17/20 Canaccord TTEC Holdings price target raised to $90 from $77 at Canaccord 10/15/20 Canaccord TTEC Holdings model steadily shifts to digital, Canaccord starts with a Buy 10/15/20 Canaccord TTEC Holdings initiated with a Buy at Canaccord 08/10/20 Fly Intel: Top five analyst downgrades TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 TTEC Holdings sees FY21 EPS $4.06-$4.25, consensus $2.96 03/01/21 TTEC Holdings reports Q4 EPS $1.22, consensus 71c 11/04/20 TTEC Holdings raises FY20 EPS view to $2.92-$3.02 from $2.37-$2.43 11/04/20 TTEC Holdings reports Q3 adjusted EPS 90c, consensus 54c TTEC TTEC Holdings $86.51 / -2.22 (-2.50%) 03/01/21 Fly Intel: After-Hours Movers

Events

Earnings calls, analyst events, roadshows and more

OPTN
Today at 08:00

Optinose - OPTN Conference Calls
BQ
Today at 08:00

Boqii - BQ Conference Calls
ISEE
Today at 08:00

Iveric bio - ISEE Conference Calls
TSHA
Today at 08:00

Taysha Gene Therapies - TSHA Conference Calls
Today at 08:15

ADP Employment Report: Private Payrolls M/M: February 2021 Government Event
PASG
Today at 08:30

Passage Bio - PASG Conference Calls
CECE
Today at 08:30

CECO Environmental - CECE Conference Calls
SBBP
Today at 08:30

Strongbridge Biopharma - SBBP Conference Calls
WEN
Today at 08:30

Wendy's - WEN Conference Calls
TAST
Today at 08:30

Carrols Restaurant - TAST Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer $9.14 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans $17.00-19.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton $32.22 10.6M Shares
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Karyopharm partners with Precision for Medicine for COVID-19 global trial

TODAY'S FREE FLY STORIES

Get Full Fly Access